PDF(Pubmed)
Abstract：
This study evaluated the immune response to vaccination against COVID-19 in 534 healthcare frontline workers in Vilnius, Lithuania. The incidence of COVID-19 was reduced significantly after vaccination started in the healthcare sector. SARS-CoV-2 antibodies were detected in groups V-VII and this level of antibodies was found to be effective in preventing COVID-19. Sustained immune response was achieved after two vaccination doses, which remained stable for up to 6 months. After the booster dose, antibody levels remained high for an additional 12 months. Although SARS-CoV-2 antibody levels decreased after 6 months, even lower levels of antibodies provided protection against the Delta strain. The booster dose distributed the antibody titer in the high-level antibody groups, offering maximum protection at 12 months. However, even individuals with high antibody titers were observed to contract COVID-19 after vaccination with a booster dose and 6 months in the presence of the Omicron strain. Unfortunately, high levels of antibodies did not provide protection against the new strain of COVID-19 (the Omicron variant), posing a risk of infection. When comparing the antibody titer of vaccinated participants without COVID-19 and those with COVID-19, the change in antibodies after vaccination was significantly lower in infected participants. Individuals with comorbidities and specific conditions had lower antibody levels.
摘要：
这项研究评估了维尔纽斯534名医疗一线工作人员对COVID-19疫苗接种的免疫反应，立陶宛。在医疗保健部门开始接种疫苗后，COVID-19的发病率显着降低。在V-VII组中检测到SARS-CoV-2抗体，发现该水平的抗体可有效预防COVID-19。在两次疫苗接种后实现了持续的免疫反应，保持稳定长达6个月。加强剂量后，抗体水平继续保持高水平12个月.尽管SARS-CoV-2抗体水平在6个月后下降，甚至更低水平的抗体提供针对Delta菌株的保护。加强剂量在高水平抗体组中分配抗体滴度，提供12个月的最大保护。然而,即使具有高抗体滴度的个体,在Omicron菌株存在的情况下,在加强免疫接种6个月后,也观察到感染COVID-19.不幸的是,高水平的抗体不能提供针对新的COVID-19菌株（Omicron变体）的保护，有感染的危险.当比较没有COVID-19的接种疫苗参与者和有COVID-19的参与者的抗体滴度时，感染参与者接种疫苗后抗体的变化显着降低。具有合并症和特定条件的个体具有较低的抗体水平。
